The claims included trade secret misappropriation claims against Twist, Dr. Leproust, Dr. Chen and Ms. Glaize, breach of contract claims against Dr. Leproust, Dr. Chen and Ms. Glaize, and breach of duty of loyalty claims against Dr. Leproust. Data source: Twist Bioscience press release. )To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option.
Twist Bioscience (TWST -13.8%) slumps on modestly higher volume in response to its disclosure that a California court has granted plaintiff Agilent's (A … Dive Brief: Twist Bioscience, a San Francisco-based biotech specializing in DNA synthesis, has filed a rebuttal of allegations made by Agilent Technologies in a now year-old lawsuit accusing Twist's CEO of stealing trade secrets. But on Wednesday, Leproust's former employer, Agilent, filed a lawsuit …
Conclusions
Agilent welcomes competition on its merits and looks forward to continuing to drive innovation in this exciting new area. Agilent’s lawsuit is pending in the Superior Court of the State of California for the County of Santa Clara, Case No. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. "Agilent launched an all-out legal assault on Twist and in the end, we not only survived, we thrived through the attack," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "We are pleased with the outcome and believe this settlement removes both the uncertainty and legal expense associated with any trial, and is in the best interest of all of our stakeholders." Technologies to resolve all claims and counterclaims in the trade secret litigation filed by Agilent on February 3, 2016. If you experience any issues with this process, please contact us for further assistance.Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has reached a settlement agreement with Agilent (News - Alert). This settlement accomplishes that.” Agilent sued Twist in 2016, alleging that Twist CEO and cofounder Emily Leproust stole trade secrets when she left Agilent to launch the provider of custom DNA products and services. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. Twist makes product for use across many industries including healthcare, industrial chemicals, agriculture and academic research. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. All rights reserved | The settlement agreement provides a license to Twist for discrete aspects of Agilent’s oligo-synthesis technology and successfully resolves all outstanding litigation between all parties. The promise and potential applications of synthetic biology are world-changing, from manufacturing chemicals and biofuels to providing breakthroughs in detecting and treating diseases.
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. This leading technology enables Agilent customers to make new and wide-ranging scientific discoveries, including groundbreaking research and development aimed at improving health and saving lives. Agilent Technologies Inc. (NYSE: A) today announced it has reached an agreement with Twist Bioscience under which Twist has agreed to pay Agilent a sum of $22.5 million to settle Agilent’s claims against Twist, as well as current and former Twist employees Emily Leproust, Siyuan Chen, and Solange Glaize. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Sing up to receive our updates and other TMCnet news! © 2020 Technology Marketing Corporation. Over the past year fast-growing Twist Bioscience has hurtled ahead under the guidance of CEO Emily Leproust. Now in its 20Computershare Investor Services can help with questions regarding individual shareholder accounting records (address changes, lost stock certificate, etc. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below.